Transforming growth factor a (TGFa) and urogastrone epidermal growth factor (URO-EGF) are mitogenic polypeptides of similar size and structure (Marquardt et al., 1983) which both interact with the same receptor. They appear to be functionally equivalent and equipotent in their ability to stimulate mitotic activity (Anzano et al., 1982) and cell differentiation (Smith et al., 1985) , but marked differences in their actions on regional blood flow have been documented (Gan et al., 1987) . Moreover, the genes for TGFa and URO-EGF are different in both structure and chromosomal location (Sporn & Roberts, 1986) . The physiological role of these peptides remains unclear, although it has been proposed by many that URO-EGF plays a role in wound healing, tissue maintenance and post-natal hepatic growth and maturation (Opleta et al., 1987) . Furthermore, evidence for a physiological function of URO-EGF is suggested by decreased milk production and increased offspring mortality produced by pregestational sialoadenectomy in mice (Okamoto & Oka, 1984) . TGFa is produced by a number of embryonic and transformed cells (Goustin et al., 1986) and increased levels of both peptides have been detected in the urine of cancer patients (Kim et al., 1985) .
Immunocytochemical studies on human tissues have shown that URO-EGF is localised in the submandibular glands, Brunner's glands (Elder et al., 1978) and in specialised cells of the stomach (Elder et al., 1986) . Immunoreactive URO-EGF has also been detected in various body fluids including urine (Gregory, 1975) , saliva, gastric juice (Gregory et al., 1979) , breast milk (Hirata & Orth, 1979) and blood, where it is thought to be contained largely in platelets (Oka & Orth, 1983) . The URO-EGF receptor is widespread and has been well characterised biochemically (Ullrich et al., 1984) and is known to be a ligand regulated receptor kinase.
It has been suggested that TGFa is functional during embryonic development and is abnormally expressed by tumour cells resulting in autocrine secretion and tumour growth promotion (Sporn & Roberts, 1985) . Although sporadic reports have appeared in the literature of TGFa concentrations in the plasma and urine (Yeh et al., 1987; Kim et al., 1985) of normal and cancer patients, to our knowledge normal adult human body tissues have not been examined for the presence of this peptide. We have, therefore, examined normal gastrointestinal tissue extracts for the presence and amounts of TGFa and URO-EGF using specific radioimmunoassays for these peptides. Extraction of acid soluble proteins Tissues were partially thawed and the dissection of mucosa from submucosa was carried out on ice. Acid-ethanol extraction of tissues was carried out using a modification of the method described by Roberts et al. (1980) for the isolation of transforming growth factors.
Tissues were homogenised using a Silverson Laboratory Mixer (Silverson Machines Ltd, Chesham, Bucks., UK) in 4 ml g-' of a solution comprising 375 ml of 95% (v/v) ethanol, 7.5 ml of concentrated HCI, 33 mg of phenylmethylsulphonyl fluoride and 1.9 mg of pepstatin. The volume was adjusted to 6 ml g-' with distilled water and extracted overnight at 4°C. Mixtures were centrifuged and pellets reextracted overnight with 4 ml g-' (original weight) of a solution containing 375 ml of 95% ethanol, 7.5 ml concentrated HCI and 105 ml distilled water. Supernatants were combined and adjusted to pH 5.2 followed by the addition of 1 ml of 2 M ammonium phosphate buffer (pH 5.2) per 85 ml extract. Two volumes of cold anhydrous ethanol and four volumes of cold anhydrous ether were added, and the mixture allowed to stand for 48 h at room temperature. The resulting precipitate was collected by filtration through Whatman no. 1 paper and redissolved in 1M acetic acid (3.5 ml-' of original tissue weight). Extracts were dialysed extensively against 0.1 M acetic acid (Spectrapor tubing, molecular weight cut-off 3,500, Spectrum Medical Industries, Los Angeles, CA).
Radioimmunoassay for hURO-EGF and hTGF Lyophilised extracts were redissolved in 5-10 ml 0.04 M phosphate buffer containing 0.15 M NaCl, 0.1 M EDTA and 0.1% sodium azide at pH 4.5 to optimise peptide dissolution. The assays were not affected by sample pH in the range 4.2-7.2. Extracts were filtered through 0.2 m Acrodisc 13 filters (Gelman Science Ltd, Northampton, UK).
Peptides and specific polyclonal antibodies to hURO-EGF and hTGFax were received as gifts from Dr H. Gregory (ICI plc) . The antibody to hTGFa was raised in sheep and the EGF antibody was raised in rabbits.
hURO-EGF (6 kDa) and hTGF (5.6 kDa) were radioiodinated using the lodogen method. The antibody to hTGFa shows non cross-reaction with hURO-EGF at a 2,000-fold greater concentration and the TGFa RIA is sensitive within the range 25 pg to 12.5 ng. The hURO-EGF antibody shows no cross reaction with hTGFa also at a 2,000-fold greater concentration and the hURO-EGF RIA is sensitive within the range 10 pg to 2.5 ng.
Reverse phase chromatography Normal gastric mucosal extract (500 gil containing 5 mg of acid soluble protein) in phosphate buffer pH 4.5 was applied to a Pep RPC 5/5 HR reverse phase column (Pharmacia Ltd, Milton Keynes, Bucks., UK) previously equilibrated with 0.1% trifluoacetic acid (TFA). The column was then eluted at a flow rate of 1 ml min-' at room temperature with a 0-40% linear gradient of acetonitrile containing 0.1% TFA.
One millilitre fractions were collected, lyophilised and redissolved in assay buffer before radioimmunoassay for hURO-EGF and hTGFx.
Results
Immunoreactive hTGFa was detected in all of the tissue extracts examined ( Figure 1) ; individual results on each sample are availabie from the authors on request. Although tissues were largely derived from only three adults, and absolute levels varied between individuals, the distribution of hTGFa throughout the gastrointestinal tract mucosa appeared similar. hTGFa levels declined significantly from the gastric mucosa (mean 2,232 pg hTGFx per gram wet weight of tissue) to the duodenal mucosa (396pgg-') and gradually rose again through the ileum (1,290 pg g') and ascending colon (2,173 pg g-') to decrease again through to the sigmoid colon mucosa (530pgg-').
EGF immunoreactivity was detected in all but two of the tissue extracts, but levels (0-216pg hURO-EGF per gram wet weight of mucosa) were much lower than hTGFa levels in the same tissue extracts. There was no apparent pattern in the distribution of hURO-EGF along the gastrointestinal tract mucosa.
To verify the nature of the observed immunoreactivity, reverse phase chromatography was carried out on samples of gastric mucosal extracts (Figure 2 ). hTGFa and hURO-EGF immunoreactivity were found to coelute exactly with hTGFa and hURO-EGF standards previously applied to the column. hTGFo eluted at 25% acetonitrile (peak retention 36 ml) and hURO-EGF at 30% acetonitrile (peak retention 42 ml).
Gastrointestinal mucosal extracts from a 7-year-old female contained higher levels of hTGFa than corresponding adult tissue extracts, with the exception of that derived from the stomach (Figure 3) , and the distribution of hTGFa was also markedly different. this age. The avidin-biotin method employed the same antibody used for hURO-EGF radioimmunoassay, and adult control tissue showed positive staining for EGF in Brunner's glands of the duodenum (data on file).
Discussion
The presence of hURO-EGF in human submandibular glands, saliva, stomach, gastric juice and Brunner's glands, together with the finding that the hURO-EGF receptor is expressed throughout the gastrointestinal mucosa, has led to the proposal that this peptide plays a role in normal gastrointestinal epiithelial maintenance. Recent studies in the rabbit suggest that hURO-EGF may play an important role in post-natal hepatic growth and maturation (Opleta et al., 1987) . The present study demonstrated that hTGFa, which also binds to and activates the hURO-EGF receptor kinase, is present throughout the normal gastrointestinal mucosa in significantly higher quantities than hURO-EGF. This finding suggests that this peptide, which until recently was thought to be tumour and embryo specific may be also involved in the control of normal cell renewal in the epithelial lining of the gut. The possibility that these peptides are not produced by the gastrointestinal mucosa but are sequestered by them cannot be discounted. Indeed, the low levels of hURO-EGF detected in most of the adult tissues may represent the peptide contained within platelets present in the mucosal samples prior to extraction. Previous work in our laboratory has shown that up to 11 ng of hURO-EGF per ml of serum can be released from platelets following the storage of whole blood from normal individuals. We have not, however, detected hTGFa in the platelets or serum of normal individuals (n = 6) or of patients suffering from gastrointestinal cancer (n = 12) (unpublished observations).
The presence of hTGFa in the stomach and duodenum, implies the simultaneous production of two distinct molecules with affinities for the same receptor. EGF in. intracellular granules positive by the immunoperoxidase technique have been described (Elder et al., 1986) , but TGFa specific localisation is not kown. The reasons for the presence of these highly similar peptides in the same tissue remain obscure. However, Derynck (1986) suggest that there are subtle differences in cellular responses to the binding of EGF and TGFa in specific in vitro and in vivo experimental models. For example, TGFa is reported to elicit a greater effect in inducing the formation of epidermal cell colonies in soft agar than does EGF; TGFo appears more effective than EGF in the induction of cell ruffling (Myrdal, 1985) and is more potent in stimulating osteoclast precursor cells (Ibbotson et al., 1986) . TGFa has also been shown to induce neovascularisation in hamster cheek pouches at much lower concentrations than EGF (Schreiber et al., 1986) , and was much more effective than EGF in terms of producing a maximum increase in blood flow in an experimental model (Gan et al., 1987) . The profile of hTGFa levels along the adult gastrointestinal tract mucosa shows lower levels in the duodenum and jejunum. Since hURO-EGF has been localised to the submucosal Brunner's glands, a reciprocal inverse relationship may exist between the two peptides in these areas of rapid cell renewal. Distally, hTGFa levels rise first and then decline again along the colon. It is interesting to note that lower levels of hTGFa and very little hURO-EGF are present in the descending and sigmoid colon, the most common sites of gastrointestinal tumour formation. In contrast, hTGFa levels detected in the extracts of colonic mucosa derived from the juvenile did not decline and in the sigmoid colon were approximately 10 times higher than in the corresponding adult tissue extracts. Colonic cancers are virtually unknown in children. However, only one juvenile has been studied and the distribution described requires confirmation by further reports.
Little is known in the human species about the regulation of hURO-EGF or hTGFa synthesis. Studies in the mouse suggest that EGF concentration in the submandibular gland is influenced by androgens, thyroid hormones, progesterone and oestrogen, probably by means of alteration of the synthesis of prepro-EGF (Gresik et al., 1981; Walker et al., 1981; Bullock et al., 1975; Kurachi & Oka, 1986; Grubits et al., 1986) . Further studies are now required to determine if the gut is a target organ for these well established regulatory hormones as regards EGF and TGFa synthesis. The area of origins, actions, physiological roles and relationship between production of EGF or TGFa to cancer induction and metastasis has recently been reviewed (Burgess, 1989) , but evidence is mounting that these peptides may be of much more physiological than pathological importance. 
